BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 34117307)

  • 1. Allele frequencies of single nucleotide polymorphisms of clinically important drug-metabolizing enzymes CYP2C9, CYP2C19, and CYP3A4 in a Thai population.
    Sukprasong R; Chuwongwattana S; Koomdee N; Jantararoungtong T; Prommas S; Jinda P; Rachanakul J; Nuntharadthanaphong N; Jongjitsook N; Puangpetch A; Sukasem C
    Sci Rep; 2021 Jun; 11(1):12343. PubMed ID: 34117307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of CYP2C19, CYP2C9 and CYP3A4 gene polymorphisms on plasma voriconazole levels in Chinese pediatric patients.
    Fan X; Zhang H; Wen Z; Zheng X; Yang Y; Yang J
    Pharmacogenet Genomics; 2022 Jun; 32(4):152-158. PubMed ID: 35081606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allele and genotype frequencies of the polymorphic cytochrome P450 genes (CYP1A1, CYP3A4, CYP3A5, CYP2C9 and CYP2C19) in the Jordanian population.
    Yousef AM; Bulatova NR; Newman W; Hakooz N; Ismail S; Qusa H; Zahran F; Anwar Ababneh N; Hasan F; Zaloom I; Khayat G; Al-Zmili R; Naffa R; Al-Diab O
    Mol Biol Rep; 2012 Oct; 39(10):9423-33. PubMed ID: 22722998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population.
    Scott SA; Edelmann L; Kornreich R; Erazo M; Desnick RJ
    Pharmacogenomics; 2007 Jul; 8(7):721-30. PubMed ID: 18240905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic Polymorphism of Drug-Metabolizing Enzymes CYP2C9 and CYP2C19 in Moroccan Population.
    Afilal D; Basselam MA; Brakez Z; Chouham S; Brehm A; Izaabel EH
    Genet Test Mol Biomarkers; 2017 May; 21(5):298-304. PubMed ID: 28282224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetic relevant polymorphisms of CYP2C9, CYP2C19, CYP2D6, and CYP3A5 in Bhutanese population.
    Dorji PW; Wangchuk S; Boonprasert K; Tarasuk M; Na-Bangchang K
    Drug Metab Pers Ther; 2019 Dec; 34(4):. PubMed ID: 32004143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic polymorphisms of drug-metabolizing phase I enzymes CYP3A4, CYP2C9, CYP2C19 and CYP2D6 in Han, Uighur, Hui and Mongolian Chinese populations.
    Zuo J; Xia D; Jia L; Guo T
    Pharmazie; 2012 Jul; 67(7):639-44. PubMed ID: 22888523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defining screening panel of functional variants of CYP1A1, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 genes in Serbian population.
    Skadrić I; Stojković O
    Int J Legal Med; 2020 Mar; 134(2):433-439. PubMed ID: 31858263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic polymorphisms of CYP2C9, CYP2C19, and CYP3A5 in Kosovar population.
    Krasniqi V; Dimovski A; Bytyqi HQ; Eftimov A; Šimičević L; Božina N
    Arh Hig Rada Toksikol; 2017 Sep; 68(3):180-184. PubMed ID: 28976882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of association between genetic polymorphisms of CYP3A4, CYP2C9 and CYP2C19 and antituberculosis drug-induced liver injury in a community-based Chinese population.
    Tang SW; Lv XZ; Chen R; Wu SS; Yang ZR; Chen DF; Zhan SY
    Clin Exp Pharmacol Physiol; 2013 May; 40(5):326-32. PubMed ID: 23469989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequencies of Genetic Polymorphisms of Clinically Relevant Gene-Drug Pairs in a German Psychiatric Inpatient Population.
    Hahn M; Müller DJ; Roll SC
    Pharmacopsychiatry; 2021 Mar; 54(2):81-89. PubMed ID: 33327018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of CYP2C19, CYP3A4, ABCB1, and FMO3 genotypes on plasma voriconazole in Thai patients with invasive fungal infections.
    Chuwongwattana S; Jantararoungtong T; Prommas S; Medhasi S; Puangpetch A; Sukasem C
    Pharmacol Res Perspect; 2020 Dec; 8(6):e00665. PubMed ID: 33124772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYP2C9 and CYP2C19 Allele and Haplotype Distributions in Four Mestizo Populations from Western Mexico: An Interethnic Comparative Study.
    Saldaña-Cruz AM; León-Moreno LC; Sánchez-Corona J; Santiago DA; Mendoza-Carrera F; Castro-Martínez XH; García-Zapién AG; Morán-Moguel MC; Flores-Martínez SE
    Genet Test Mol Biomarkers; 2016 Nov; 20(11):702-709. PubMed ID: 27617498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of genetic variants of CYP2D6, CYP2C9, CYP2C19 and CYP3A4 on antiepileptic drug metabolism in pediatric patients with refractory epilepsy.
    López-García MA; Feria-Romero IA; Serrano H; Rayo-Mares D; Fagiolino P; Vázquez M; Escamilla-Núñez C; Grijalva I; Escalante-Santiago D; Orozco-Suarez S
    Pharmacol Rep; 2017 Jun; 69(3):504-511. PubMed ID: 28343093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of temperature on the metabolic activity of CYP2C9, CYP2C19, and CYP3A4 genetic variants
    Kojima M; Machida K; Cho S; Watanabe D; Seki H; Shimoji M; Imaoka A; Yamazaki H; Guengerich FP; Nakamura K; Yamamoto K; Akiyoshi T; Ohtani H
    Xenobiotica; 2023 May; 53(5):357-365. PubMed ID: 37584614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relevance of the ancestry for the variability of the Drug-Metabolizing Enzymes CYP2C9, CYP2C19 and CYP2D6 polymorphisms in a multiethnic Costa Rican population.
    Céspedes-Garro C; Rodrigues-Soares F; Jiménez-Arce G; Naranjo MG; Tarazona-Santos E; Fariñas H; Barrantes R; Llerena A;
    Rev Biol Trop; 2016 Sep; 64(3):1067-76. PubMed ID: 29461783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population.
    Arvanitidis K; Ragia G; Iordanidou M; Kyriaki S; Xanthi A; Tavridou A; Manolopoulos VG
    Fundam Clin Pharmacol; 2007 Aug; 21(4):419-26. PubMed ID: 17635181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interethnic Variability in CYP2D6, CYP2C9, and CYP2C19 Genes and Predicted Drug Metabolism Phenotypes Among 6060 Ibero- and Native Americans: RIBEF-CEIBA Consortium Report on Population Pharmacogenomics.
    Naranjo MG; Rodrigues-Soares F; Peñas-Lledó EM; Tarazona-Santos E; Fariñas H; Rodeiro I; Terán E; Grazina M; Moya GE; López-López M; Sarmiento AP; Calzadilla LR; Ramírez-Roa R; Ortiz-López R; Estévez-Carrizo FE; Sosa-Macías M; Barrantes R; LLerena A;
    OMICS; 2018 Sep; 22(9):575-588. PubMed ID: 30183544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VARIANTS OF THE FORMATION AND COURSE OF DRUG-RESISTANT EPILEPSY IN CHILDREN WITH GENETIC POLYMORPHISMS OF CYP2C9, CYP2C19, CYP3A4.
    Tantsura LM; Pylypets OY; Tretiakov DV; Tantsura YO
    Wiad Lek; 2023; 76(5 pt 1):1007-1013. PubMed ID: 37326083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytochrome P450 1A1, 2C9, 2C19, and 3A4 Polymorphisms Account for Interindividual Variability of Toxicological Drug Metabolism in Cynomolgus Macaques.
    Uno Y; Uehara S; Murayama N; Yamazaki H
    Chem Res Toxicol; 2018 Dec; 31(12):1373-1381. PubMed ID: 30412386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.